Phase III JADE Compare trial: JAK1 inhibitor abrocitinib treats atopic dermatitis with positive results

Pfizer Incon Wednesday released a set of data showing that its research JAK1 inhibitor abrocitinib treated adults with moderate to severe asexual dermatitis in phase III JADE Compare trialreached the main endpointThe company said the findings, along with previously reported Phase III JADE MONO-1 and JADE MONO-2 trial data, would support FDA regulatory filingsThe JADE Compare trial recruited 797 patients with moderate to severe asymptomatic dermatitisThe main endpoint is to reach IGA clear or almost clear at week 12, with an eczema area and severity index (EASI75) score of 75% or higher than the baselineThe top line results showed that the percentage of patients who reached the end of the primary therapeutic end at the end of the 12th week was statistically better than placebo, a role Pfizer said lasted until the 16th weekasexual dermatitis is a chronic, itchy, inflammatory skin disease that most commonly occurs in children but also affects many adultsClinical features of asexual dermatitis include dry skin, erythema, oozing and knotting, and moss-like changeItching is a sign of the disease and is a major cause of the burden of illness on patients and their families